CyberOncology Network Project: a supplementary study

Feasibility study to establish a real-world database on the actual treatment of unresectable advanced or metastatic gastric cancer using CyberOncology - CONNECT: a supplementary study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049238

Enrollment

150

Registered

2022-10-18

Start date

2022-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced or metastatic gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed epithelial malignancy. 2) Unresectable advanced or recurrent disease. 3) Primary tumor is located in the stomach or esophagogastric junction (Siewert type II-III). 4) The patient is scheduled to receive cancer chemotherapy at the participating institution (regardless of the line of therapy). 5) Consent to participate in this study has been obtained.

Exclusion criteria

Exclusion criteria: Cases that the researcher deems inappropriate for participating in this study.

Design outcomes

Primary

Measure	Time frame
Multicenter integrated data 1. HER2 testing rate 2. MSI testing rate 3. Percentage of patients receiving chemotherapy (by treatment line) 4. Chemotherapy regimen (per treatment line) 5. Patient background (organ function, comorbidities, medical history, etc.) 6. Response rate (RECIST ver 1.1) 7. Disease control rate (RECIST ver 1.1) 8. Progression-free survival 9. Successful treatment period 10. Overall survival 11. Adverse events (CTCAE ver 5.0) 12. Serious adverse events	—

Measure

Time frame

Multicenter integrated data 1. HER2 testing rate 2. MSI testing rate 3. Percentage of patients receiving chemotherapy (by treatment line) 4. Chemotherapy regimen (per treatment line) 5. Patient background (organ function, comorbidities, medical history, etc.) 6. Response rate (RECIST ver 1.1) 7. Disease control rate (RECIST ver 1.1) 8. Progression-free survival 9. Successful treatment period 10. Overall survival 11. Adverse events (CTCAE ver 5.0) 12. Serious adverse events

—

Countries

Japan

Contacts

Public ContactShigenori Kadowaki

Aichi Cancer Center Hospital Department of Clinical Oncology

skadowaki@aichi-cc.jp052-762-6111

Outcome results